Teleflex Incorporated TFX
161.58 USD -1.82 (-1.11%)
Regular-session close
161.58 0.00 0.00%
After hours · Nov 20, 4:00 PM ET
161.47 Day range 166.52
100.34 52-week range 165.85
- YTD
- +32.40%
- 1 year
- +54.42%
News
seekingalpha.com Teleflex Incorporated (TFX) Presents at Jefferies Global Healthcare Conference 2026 Transcript Teleflex Incorporated (TFX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
benzinga.com Seth Klarman’s Baupost Group Takes New Position in Honeywell Aerospace in Q3 A look at the portfolio changes for Baupost Group from Q2 to Q3 and the new stocks Seth Klarman is betting on.benzinga.com Truist Securities Maintains Hold on Teleflex, Raises Price Target to $167 Truist Securities analyst Ravi Misra maintains Teleflex (NYSE:TFX) with a Hold and raises the price target from $142 to $167.
benzinga.com RBC Capital Maintains Outperform on Teleflex, Raises Price Target to $175 RBC Capital analyst Kendall Au maintains Teleflex (NYSE:TFX) with a Outperform and raises the price target from $155 to $175.
benzinga.com Wells Fargo Maintains Equal-Weight on Teleflex, Raises Price Target to $167 Wells Fargo analyst Larry Biegelsen maintains Teleflex (NYSE:TFX) with a Equal-Weight and raises the price target from $138 to $167.
benzinga.com Teleflex Q3 2026 Earnings Call Transcript Teleflex (NYSE:TFX) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…benzinga.com Teleflex Raises FY2026 Adj EPS Guidance from $6.90-$7.20 to $7.50-$7.75 vs $7.22 Est; Lowers FY2026 Sales Guidance from $2.260B-$2.280B to $2.256B-$2.276B vs $2.269B Est Teleflex (NYSE:TFX) raises FY2026 Adj EPS guidance from $6.90-$7.20 to $7.50-$7.75 vs $7.22 analyst estimate. Lowers FY2026 sales outlook from $2.260 billion-$2.280 billion to $2.256 billion-$2.276…
benzinga.com Teleflex Q3 Adj. EPS $2.63 Beats $1.90 Estimate, Sales $567.800M Beat $566.772M Estimate Teleflex (NYSE:TFX) reported quarterly earnings of $2.63 per share which beat the analyst consensus estimate of $1.90 by 38.42 percent. The company reported quarterly sales of $567.800 million which…
benzinga.com Teleflex Receives FDA Breakthrough Device Designation For Its Freesolve Resorbable Magnesium Scaffold For Percutaneous Coronary Intervention To qualify for a BDD, device technology must address an unmet clinical need and show that it has the potential to provide for more effective treatment of life-threatening diseases or irreversibly…
